信息披露义务人：李男行 浙江医药股份有限公司 详式权益变动报告书 浙江医药股份有限公司 详式权益变动报告书 住所：浙江省新昌县南明街道**** 通讯地址：浙江省绍兴滨海新城致远中大道 168 号 股份变动性质：增加 一致行动人：李春波 住所：浙江省新昌县城关镇**** 通讯地址：浙江省新昌县城关镇江南南路 47 号 签署日期：2024 年 11 月 1 日 1 上市公司名称：浙江医药股份有限公司 股票上市地点：上海证券交易所 股票简称：浙江医药 股票代码：600216 浙江医药股份有限公司 详式权益变动报告书 信息披露义务人声明 一、本报告书系依据《中华人民共和国证券法》《上市公司收购管理办法》 《公开发行证券的公司信息披露内容与格式准则第 15 号——权益变动报告书》 《公开发行证券的公司信息披露内容与格式准则第 16 号——上市公司收购报告 书》等相关的法律、法规及规范性文件编写。 二、信息披露义务人及其一致行动人签署本报告书已获得必要的授权和批准， 其履行亦不违反信息披露义务人及其一致行动人所适用的章程或内部规则中的 任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》的规 ...

证券代码：600216 证券简称：浙江医药 公告编号：2024-027 浙江医药股份有限公司 关于控股股东股权结构变更 暨实际控制人变更的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司实际控制人李春波先生拟将其持有的公司控股股东新昌县昌欣投资 发展有限公司（以下简称"昌欣投资"）的全部股权转让给其子李男行先生。 截至目前，公司控股股东昌欣投资持有公司 21.65%股份。本次权益变动 系控股股东昌欣投资的股权结构变更，不涉及昌欣投资所持公司股份的变动，不 触及要约收购，不会导致公司控股股东发生变更，公司控股股东仍为昌欣投资。 重要内容提示： 本次权益变动完成后，李男行先生将通过其控制的昌欣投资间接控制上 市公司 21.65%股份，公司的实际控制人将由李春波先生变更为李男行先生。 近日公司收到控股股东昌欣投资发来的《关于股权结构变更的告知函》，得 知公司实际控制人李春波先生与李男行先生于 2024 年 10 月 29 日签订了《股权 转让协议》。根据协议约定，李春波先生将其持有的昌欣投资 60.00%股权以人民 ...

Investment Rating - The report maintains a "Buy" rating for Zhejiang Medicine (600216.SH) [1][6][7] Core Views - The company reported strong performance in the first three quarters of 2024, with revenue, net profit attributable to shareholders, and net profit excluding non-recurring items reaching 7.113 billion, 850 million, and 846 million RMB respectively, representing year-on-year growth of 21%, 182%, and 227% [1] - The third quarter alone saw revenue, net profit attributable to shareholders, and net profit excluding non-recurring items of 2.707 billion, 534 million, and 529 million RMB, with year-on-year growth of 39.66%, 1738%, and 2564% respectively, exceeding expectations [1] - The increase in profitability is primarily attributed to the strong rise in vitamin prices, with gross margin increasing from 33.57% in the same period last year to 40.85% [1] - The company’s antibiotic segment is experiencing growth despite a slight decline in gross margin, with vancomycin already commercialized in the U.S. and expected to maintain its performance [1] Summary by Sections Performance Analysis - Revenue for the first three quarters of 2024 was 71.13 billion RMB, with net profit attributable to shareholders and net profit excluding non-recurring items at 8.50 billion and 8.46 billion RMB, respectively, marking significant increases compared to the previous year [1] - The gross margin for the first three quarters showed a steep increase, with quarterly margins of 32.92%, 37.98%, and 47.64% [1] Vitamin Segment - The revenue and profit growth is largely driven by the price increases of vitamins A and E, influenced by production cuts from international giants like BASF and DSM [1] - A fire incident at BASF's facility in Germany has further constrained supply, leading to a strong rebound in vitamin prices [1] Antibiotic Segment - The antibiotic manufacturing segment is focused on international expansion and volume growth, with a 5% revenue increase despite a 4.85 percentage point decline in gross margin [1] - The revenue from vancomycin in the U.S. reached 220 million RMB in the first half of 2024, reflecting a 28% year-on-year growth [1] Future Outlook - The report maintains revenue forecasts of 9.2 billion, 10 billion, and 10.8 billion RMB for 2024, 2025, and 2026 respectively, while adjusting net profit forecasts upward by 34%, 13%, and 4% to 900 million, 1 billion, and 1.1 billion RMB [1]

Investment Rating - The report maintains a "Buy" rating for Zhejiang Medicine, indicating an expected stock price increase of over 15% relative to the industry index in the next six months [15]. Core Views - The company achieved record high performance in Q3 2024, with total revenue reaching 7.113 billion yuan, a year-on-year increase of 21.04%, and net profit attributable to shareholders at 850 million yuan, up 181.96% [1][2]. - The growth momentum from Q2 2024 continues, driven by strong performance in the vitamin E and A segments, with both volume and price increases contributing to the results [2][4]. - The approval of the "Segmented Production Pilot Work Plan for Biological Products" by the National Medical Products Administration is expected to facilitate the approval process for the company's innovative drug ARX788, potentially driving long-term growth [6][7]. Financial Summary - For the first three quarters of 2024, the company reported a gross profit margin of 40.05%, an increase of 6.48 percentage points year-on-year [2]. - The net profit margin for the same period was 10.66%, up 7.58 percentage points from the previous year, primarily due to rising prices of vitamin E and A [2]. - The company’s cash flow from operating activities increased by 68.51% year-on-year, reaching 692 million yuan [3]. Revenue and Profit Forecast - The projected revenues for 2024, 2025, and 2026 are 10.213 billion yuan, 11.074 billion yuan, and 11.861 billion yuan, respectively, with corresponding net profits of 1.573 billion yuan, 1.705 billion yuan, and 1.770 billion yuan [7]. - The expected EPS for the same years is 1.63 yuan, 1.77 yuan, and 1.83 yuan, with current P/E ratios of 5.8X, 5.4X, and 5.2X [7]. Market Conditions - The vitamin E and A prices are expected to remain strong, with the domestic market prices for vitamin A and E significantly higher than the average prices in 2023 [4]. - The report highlights that there are no new players or production capacity expected in the short term, which is favorable for the company's performance in the vitamin segment [7].

Financial Performance - Revenue for Q3 2024 reached CNY 2,707,337,059.93, an increase of 39.66% compared to the same period last year[2] - Net profit attributable to shareholders was CNY 534,319,800.14, a significant increase of 1,737.57% year-on-year[2] - Net profit excluding non-recurring gains and losses for the period was CNY 529,302,742.23, up 2,564.26% from the previous year[2] - Year-to-date revenue reached CNY 7,112,804,346.30, reflecting a growth of 21.04% compared to the same period last year[2] - Year-to-date net profit attributable to shareholders was CNY 849,651,818.01, an increase of 181.96% year-on-year[2] - Basic earnings per share for Q3 2024 were CNY 0.56, up 1,766.67% from the same period last year[3] - Total operating revenue for the first three quarters of 2024 reached CNY 7,112,804,346.30, a significant increase of 21.0% compared to CNY 5,876,518,447.27 in the same period of 2023[12] - Net profit for the first three quarters of 2024 was CNY 758,558,082.68, compared to CNY 180,865,708.32 in 2023, indicating a substantial increase of 319.5%[14] - The total comprehensive income attributable to shareholders of the parent company is ¥848,266,025.98, compared to ¥306,821,011.56 in the same period last year, reflecting a strong overall performance[15] Assets and Liabilities - Total assets at the end of the reporting period were CNY 13,429,512,113.31, a 5.09% increase from the end of the previous year[3] - The total assets of the company as of the end of Q3 2024 amounted to CNY 13,429,512,113.31, up from CNY 12,779,539,756.21 at the end of Q3 2023, representing a growth of 5.1%[12] - The total liabilities increased slightly to CNY 2,820,110,790.11 in Q3 2024 from CNY 2,793,145,986.32 in Q3 2023, showing a growth of 1.0%[12] - Shareholders' equity attributable to shareholders was CNY 10,341,301,291.01, reflecting a 7.38% increase year-on-year[3] - The total equity attributable to shareholders reached CNY 10,341,301,291.01 in Q3 2024, up from CNY 9,630,715,541.49 in Q3 2023, indicating an increase of 7.4%[12] Cash Flow - The company reported a net cash flow from operating activities of CNY 692,060,136.95 for the year-to-date, an increase of 68.51% compared to the previous year[3] - Cash flow from operating activities for the first three quarters of 2024 is ¥692,060,136.95, compared to ¥410,703,114.95 in the same period of 2023, reflecting a strong operational performance[17] - The total amount of cash and cash equivalents as of September 30, 2024, was RMB 1,635,716,620.56, up from RMB 1,460,026,640.19, reflecting an increase of approximately 12%[10] - The company's cash and cash equivalents increased to CNY 1,000,000,000.00 in Q3 2024, compared to CNY 800,000,000.00 in Q3 2023, reflecting a growth of 25.0%[12] - The cash and cash equivalents at the end of the period amount to ¥1,635,529,620.56, up from ¥1,349,552,417.87 at the end of the previous year, showing improved liquidity[18] - The company experienced a net increase in cash and cash equivalents of ¥175,689,980.37, compared to a decrease of -¥88,356,849.04 in the same period last year, indicating better cash management[18] Shareholding Structure - The company reported a total of 208,192,361 shares held by New Changxin Investment Development Co., Ltd., making it the largest shareholder[8] - The second-largest shareholder, Guotou High-tech Investment Co., Ltd., holds 151,127,573 shares, representing a significant stake in the company[8] - The company has no significant changes in the shareholding structure among the top 10 shareholders compared to the previous period[9] Operational Insights - The increase in revenue and profit was primarily driven by higher sales and prices of key products, including Vitamin E and Vitamin A[5] - Operating costs for the first three quarters of 2024 were CNY 6,103,341,032.99, up from CNY 5,607,285,954.16 in 2023, reflecting a growth of 8.8%[12] - Research and development expenses for the first three quarters of 2024 were CNY 546,930,073.32, a decrease of 9.9% from CNY 607,134,841.28 in the same period of 2023[14] - The company has not reported any significant new product developments or technological advancements during this quarter[9] - There are no notable mergers or acquisitions reported in the current quarter, and the company has not disclosed any new strategic initiatives[9] Inventory and Receivables - As of September 30, 2024, total current assets reached RMB 6,146,702,104.36, an increase from RMB 5,601,409,763.89 at the end of December 2023, reflecting a growth of approximately 9.7%[10] - Accounts receivable increased to RMB 1,690,337,783.45 from RMB 1,252,230,303.53, representing a significant rise of about 35%[10] - Inventory decreased to RMB 1,945,483,588.92 from RMB 2,010,704,310.63, indicating a reduction of approximately 3.2%[10] Long-term Borrowings - The company’s long-term borrowings increased to CNY 372,307,500.00 in Q3 2024 from CNY 230,222,800.00 in Q3 2023, reflecting a growth of 61.6%[12]

包装规格：5 支/盒 注册分类：化学药品 证券代码：600216 证券简称：浙江医药 公告编号：2024-026 浙江医药股份有限公司关于公司药品重酒石酸间羟胺注射液 通过仿制药一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江医药股份有限公司（以下简称"公司"）近日收到国家药品监督管理局 核准签发的重酒石酸间羟胺注射液《药品补充申请批准通知书》，批准该药品通 过仿制药质量和疗效一致性评价（以下简称"一致性评价"）。现将相关情况公告 如下： 一、药品基本情况 药品名称：重酒石酸间羟胺注射液 剂型：注射剂 规格：1ml:10mg（按 C₉H₁₃NO₂计） 重酒石酸间羟胺注射液主要用于防治椎管内阻滞麻醉时发生的急性低血压； 由于出血、药物过敏，手术并发症及脑外伤或脑肿瘤合并休克而发生的低血压， 本品可用于辅助性对症治疗；也可用于心源性休克或败血症所致的低血压。 重酒石酸间羟胺注射液最早由默克制药研发，于 1954 年在美国上市。根据 国家药品监督管理局网站信息显示，中国大陆已批准上市的重酒石酸间羟胺注射 ...

证券代码：600216 证券简称：浙江医药 公告编号：2024-025 浙江医药股份有限公司 关于召开 2024 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （网址：https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频直播和网络互动 投资者可于 2024 年 09 月 03 日(星期二)至 09 月 09 日(星期 一)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 board@zmc-china.com 进行提问。公司将在说明会上对 投资者普遍关注的问题进行回答。 浙江医药股份有限公司（以下简称"公司"）已于 2024 年 8 月 23 日发布公司 2024 年半年度报告，为便于广大投资者更全面深入地 了解公司 2024 年半年度经营成果、财务状况，公司计划于 2024 年 09 月 10 日下午 15:00-16:30 举行 2024 年半年度业绩说明会，就投 资者关心的问题进行交流。 一、说明会类型 本次投 ...

2024 年 8 月 23 日 收益表现 % 1M 3M 1Y 相对 22.65 55.05 54.98 绝对 18.96 46.03 44.61 资料来源：Wind 公司研究 维生素景气度持续回暖，24Q2 业绩环比大幅增长 ——浙江医药（600216.SH）2024 年半年报点评 买入（维持） 当前价：14.68 元 作者 分析师：赵乃迪 执业证书编号：S0930517050005 010-57378026 zhaond@ebscn.com 分析师：蔡嘉豪 执业证书编号：S0930523070003 021-52523800 caijiahao@ebscn.com 市场数据 总股本(亿股) 9.62 总市值(亿元)： 141.17 一年最低/最高(元)： 7.86/17.50 近 3 月换手率： 247.75% 股价相对走势 -25% -5% 14% 33% 52% 08/23 11/23 02/24 05/24 浙江医药 沪深300 相关研报 维生素触底回暖 Q1 业绩显著修复，重视研 发医药业务进展有序——浙江医药 （600216.SH）23 年年报&24 年一季报点评 （2024-04-30） 维生 ...

来源：公司年报、国金证券研究所 浙江医药 (600216.SH) 买入(维持评级) 公司点评 事件 2024 年 8 月 22 日，公司公告，2024 年上半年营收/归母/扣非净 利润 44.05/3.15/3.17 亿元，分别同比增长 11.87%/15.82%/ 32.56%。2024 年二季度营收营收/归母/扣非净利润 21.56/2.06/ 2.11 亿元，分别同比增长 11.73%/29.60%/49.62。业绩符合预期。 点评 维生素强劲回升，万古霉素爬坡放量，业绩转入上升态势明确。 （1）总体：公司上半年营收 44 亿，其中,生命营养品、医药制造、 医药商业板块分别收入 20.2/11.6/11.9 亿 元 , 同比增长 24%/5%/5%。这三大板块的毛利分别为 5.5/7.3/0.5 亿元，生命营 养品板块同比增长 44%，医药制造同比下降 3%，医药商业持平。 （2）维生素：生命营养品板块的维生素系列（A、E）营收 17.35 亿元，同比增长 23%；毛利 5.15 亿元，同比增长 47%；毛利率同 比提升 7 个百分点。随着寡头垄断的维生素行业中，巴斯夫、帝 斯曼等国际巨头限产等情况，我 ...

来源：公司年报、国金证券研究所 浙江医药 (600216.SH) 买入(维持评级) 公司点评 事件 2024 年 8 月 22 日，公司公告，2024 年上半年营收/归母/扣非净 利润 44.05/3.15/3.17 亿元，分别同比增长 11.87%/15.82%/ 32.56%。2024 年二季度营收营收/归母/扣非净利润 21.56/2.06/ 2.11 亿元，分别同比增长 11.73%/29.60%/49.62。业绩符合预期。 点评 维生素强劲回升，万古霉素爬坡放量，业绩转入上升态势明确。 （1）总体：公司上半年营收 44 亿，其中,生命营养品、医药制造、 医药商业板块分别收入 20.2/11.6/11.9 亿 元 , 同比增长 24%/5%/5%。这三大板块的毛利分别为 5.5/7.3/0.5 亿元，生命营 养品板块同比增长 44%，医药制造同比下降 3%，医药商业持平。 （2）维生素：生命营养品板块的维生素系列（A、E）营收 17.35 亿元，同比增长 23%；毛利 5.15 亿元，同比增长 47%；毛利率同 比提升 7 个百分点。随着寡头垄断的维生素行业中，巴斯夫、帝 斯曼等国际巨头限产等情况，我 ...